DK0667901T4 - Hidtil ukendt cytokin - Google Patents

Hidtil ukendt cytokin

Info

Publication number
DK0667901T4
DK0667901T4 DK92925017T DK92925017T DK0667901T4 DK 0667901 T4 DK0667901 T4 DK 0667901T4 DK 92925017 T DK92925017 T DK 92925017T DK 92925017 T DK92925017 T DK 92925017T DK 0667901 T4 DK0667901 T4 DK 0667901T4
Authority
DK
Denmark
Prior art keywords
hitherto unknown
unknown cytokine
cytokine
hitherto
immunogen
Prior art date
Application number
DK92925017T
Other languages
Danish (da)
English (en)
Other versions
DK0667901T3 (da
Inventor
Richard J Armitage
William C Fanslow
Melanie K Spriggs
Srinivasan Subhashini
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27120174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0667901(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of DK0667901T3 publication Critical patent/DK0667901T3/da
Application granted granted Critical
Publication of DK0667901T4 publication Critical patent/DK0667901T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK92925017T 1991-10-25 1992-10-23 Hidtil ukendt cytokin DK0667901T4 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78370791A 1991-10-25 1991-10-25
US80572391A 1991-12-05 1991-12-05
PCT/US1992/008990 WO1993008207A1 (en) 1991-10-25 1992-10-23 Novel cytokine

Publications (2)

Publication Number Publication Date
DK0667901T3 DK0667901T3 (da) 2004-12-27
DK0667901T4 true DK0667901T4 (da) 2008-11-10

Family

ID=27120174

Family Applications (3)

Application Number Title Priority Date Filing Date
DK97117514T DK0822199T3 (da) 1991-10-25 1992-10-23 N-terminalt monopegylerede polypeptider og fremgangsmåder til fremstilling heraf
DK98113461T DK0897983T3 (da) 1991-10-25 1992-10-23 Antistoffer mod CD40-L
DK92925017T DK0667901T4 (da) 1991-10-25 1992-10-23 Hidtil ukendt cytokin

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK97117514T DK0822199T3 (da) 1991-10-25 1992-10-23 N-terminalt monopegylerede polypeptider og fremgangsmåder til fremstilling heraf
DK98113461T DK0897983T3 (da) 1991-10-25 1992-10-23 Antistoffer mod CD40-L

Country Status (13)

Country Link
EP (2) EP0897983B1 (de)
JP (2) JP3308534B2 (de)
KR (1) KR100283541B1 (de)
AT (2) ATE239790T1 (de)
AU (1) AU661360B2 (de)
CA (2) CA2121798C (de)
DE (2) DE69233051T2 (de)
DK (3) DK0822199T3 (de)
ES (2) ES2198025T3 (de)
FI (2) FI116850B (de)
HK (1) HK1019343A1 (de)
NO (2) NO317625B1 (de)
WO (1) WO1993008207A1 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981724A (en) * 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US7070777B1 (en) * 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US6472510B1 (en) 1992-02-14 2002-10-29 Bristol-Myers Squibb Company CD40 receptor ligands
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
AU5098493A (en) * 1992-08-21 1994-03-15 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
DE69423806T2 (de) * 1993-01-22 2000-08-17 Kanegafuchi Chemical Ind Therapeutisches Agens für NIDDM
CA2153806C (en) * 1993-01-22 2005-11-08 Melanie K. Spriggs Detection and treatment of mutations in a cd40 ligand gene
ZA946765B (en) 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
IL110852A (en) * 1993-09-02 1999-05-09 Dartmouth College Methods of prolonged suppression of humoral activity
CN1127351C (zh) * 1993-09-02 2003-11-12 达特茅斯学院理事 诱导抗原特异性ｔ细胞耐受的方法
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
AU1059095A (en) * 1993-11-24 1995-06-13 Australian National University, The Treatment of viral disease with cd40l peptide
JPH09507074A (ja) * 1993-12-23 1997-07-15 イミュネックス・コーポレーション Ｃｄ４０を発現する腫瘍細胞を特徴とする疾患の予防又は治療方法
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
MX9605088A (es) 1994-04-28 1997-08-30 Boehringer Ingelheim Pharma Metodos para proliferar y diferenciar celulas b y sus usos.
NZ305083A (en) * 1995-03-01 1999-06-29 Immunex Corp Use of cd40 binding proteins (a cd40 ligand or monoclonal antibody that specifically binds to cd40) for stimulating a immune response
AU2556195A (en) 1995-03-13 1996-10-02 Regents Of The University Of Michigan, The CD40 binding compositions and methods of using same
DK0832229T3 (da) * 1995-06-07 2004-05-03 Immunex Corp CD40L-mutein
DK0833847T3 (da) * 1995-06-22 2003-12-29 Biogen Inc Krystaller af fregmenter af CD40-ligand og deres anvendelse
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
WO1997047390A1 (en) * 1996-06-14 1997-12-18 University Of Washington Absorption-enhanced differential extraction device
US6017527A (en) * 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
WO1998001538A1 (en) * 1996-07-10 1998-01-15 Immunex Corporation Method of activating dendritic cells
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
EP0951551B9 (de) 1996-12-23 2012-12-26 Immunex Corporation Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
DE69939822D1 (de) 1998-05-14 2008-12-11 Immunex Corp Verfahren zur hemmung der wirkung der osteoklasten
EP1124961B9 (de) * 1998-10-23 2010-07-21 Kirin-Amgen Inc. Thrombopoietin substitute
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
EP1067194A1 (de) * 1999-04-16 2001-01-10 F. Hoffmann-La Roche Ag Vektoren, die Gene enthalten, die für CD40 und/oder CD40L kodieren die unter der Kontrolle von einer Cytokin-induzierbaren Promotorsequenz sind. Dieser Promotor stammt von einem menschlischen akutphasen-Serumamyloid-A-Gen. Verfahren zur Herstellung derselben und Verwendung davon
WO2000063395A1 (en) * 1999-04-16 2000-10-26 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
AU6934600A (en) 1999-08-27 2001-03-26 Board Of Regents, The University Of Texas System Cd40 ligand and cd40 agonist compositions and methods of use
GB9927757D0 (en) * 1999-11-25 2000-01-26 Kennedy Rheumatology Inst Treatment of autoimmune diseases
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
AU2001261585B2 (en) 2000-05-12 2006-08-31 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
WO2002028905A2 (en) 2000-10-02 2002-04-11 Chiron Corporation Human anti-cd40 antibodies
WO2002036769A2 (en) * 2000-10-31 2002-05-10 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US6586245B2 (en) 2001-07-18 2003-07-01 Isis Pharmaceuticals, Inc. Antisense modulation of CD40 ligand expression
WO2003011324A1 (en) * 2001-07-31 2003-02-13 Genset S.A. Agonists and antagonists of moxifin for the treatment of metabolic disorders
LT1434871T (lt) 2001-09-20 2017-04-10 Immunex Corporation Heteromerinius polipeptidus ekspresuojančių ląstelių atranka
US7786282B2 (en) 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
US7494805B2 (en) 2003-02-14 2009-02-24 Biogen Idec Ma Inc. Expression cassette and vector for transient or stable expression of exogenous molecules
US8647625B2 (en) 2004-07-26 2014-02-11 Biogen Idec Ma Inc. Anti-CD154 antibodies
DE602005025005D1 (de) 2004-10-07 2011-01-05 Argos Therapeutics Inc Zusammensetzungen reifer dendritischer zellen und verfahren zu deren kultivierung
US8513008B2 (en) * 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
SG156672A1 (en) 2004-10-22 2009-11-26 Amgen Inc Methods for refolding of recombinant antibodies
MY161866A (en) 2006-09-13 2017-05-15 Abbvie Inc Cell culture improvements
EP2500416A1 (de) 2006-09-13 2012-09-19 Abbott Laboratories Verbesserungen an Zellkulturen
EP2066339B1 (de) 2006-09-18 2014-08-13 The Board Of Trustees Of The University Of Arkansas Zusammensetzungen und verfahren zur verstärkung von immunreaktionen
MX2010002683A (es) 2007-09-14 2010-03-26 Amgen Inc Poblaciones de anticuerpos homogeneos.
US9125854B2 (en) 2007-10-30 2015-09-08 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
EP3097926B1 (de) 2007-11-01 2019-10-02 The Board of Trustees of the University of Arkansas Zusammensetzungen und verfahren zur verstärkung von immunreaktionen gegenüber eimeria
WO2009091912A2 (en) 2008-01-15 2009-07-23 Abbott Laboratories Improved mammalian expression vectors and uses thereof
RS56484B1 (sr) 2009-11-17 2018-01-31 Squibb & Sons Llc Metode za poboljšanu proizvodnju proteina
JP6242050B2 (ja) 2010-01-21 2017-12-06 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 免疫応答を増強するワクチンベクターおよび方法
KR101881611B1 (ko) 2010-06-09 2018-07-25 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 캄필로박터 감염을 감소시키기 위한 백신 및 방법
ES2968398T3 (es) 2013-02-14 2024-05-09 Univ Arkansas Composiciones y métodos para potenciar las respuestas inmunitarias a Eimeria o limitar la infección por Eimeria
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
EP3578190A1 (de) 2013-03-15 2019-12-11 The Board of Trustees of the University of Arkansas Zusammensetzungen und verfahren zur verstärkung der immunreaktionen gegen enterale pathogene
EP3943098A3 (de) 2015-07-16 2022-05-11 Biokine Therapeutics Ltd. Zusammensetzungen und verfahren zur behandlung von krebs
EA201890434A1 (ru) 2015-08-05 2018-10-31 Янссен Байотек, Инк. Антитела к cd154 и способы их применения
WO2017083604A1 (en) 2015-11-12 2017-05-18 Amgen Inc. Triazine mediated pharmacokinetic enhancement of therapeutics
AR108688A1 (es) 2016-05-03 2018-09-19 Univ Arkansas Vector de vacuna de levadura que incluye polipéptidos inmunoestimuladores y antigénicos, métodos para su uso
ES2914118T3 (es) 2016-05-11 2022-06-07 Amgen Inc Selección directa de células que expresan niveles altos de proteínas heterodiméricas usando vectores de complementación intragénica de glutamina sintetasa
EP3585425A4 (de) 2017-02-27 2020-10-28 Shattuck Labs, Inc. Verfahren zur herstellung und verwendung extrazellulärer domänenbasierter chimärer proteine
JP7121029B2 (ja) * 2017-02-27 2022-08-17 シャタック ラボ，インコーポレイテッド Ｃｓｆ１ｒベースのキメラタンパク質

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104684A0 (en) * 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation

Also Published As

Publication number Publication date
EP0897983A3 (de) 1999-03-17
CA2121798A1 (en) 1993-04-29
EP0897983B1 (de) 2003-05-07
DE69233051D1 (de) 2003-06-12
ES2227513T5 (es) 2009-04-01
DE69233051T2 (de) 2004-03-11
DK0897983T3 (da) 2003-08-11
FI116828B (fi) 2006-03-15
HK1019343A1 (en) 2000-02-03
FI941837A (fi) 1994-05-30
NO941422L (de) 1994-06-27
EP0667901A4 (de) 1995-06-22
FI116850B (fi) 2006-03-15
NO320073B1 (no) 2005-10-17
DK0822199T3 (da) 2004-12-27
CA2121798C (en) 2007-07-24
FI981765A (fi) 1998-08-17
DE69233402T3 (de) 2009-06-25
CA2312667A1 (en) 1993-04-29
NO980030D0 (no) 1998-01-05
NO941422D0 (no) 1994-04-19
ATE239790T1 (de) 2003-05-15
EP0667901A1 (de) 1995-08-23
JPH07504083A (ja) 1995-05-11
EP0897983A2 (de) 1999-02-24
KR100283541B1 (ko) 2001-03-02
FI941837A0 (fi) 1994-04-20
DK0667901T3 (da) 2004-12-27
ES2198025T3 (es) 2004-01-16
JP3308534B2 (ja) 2002-07-29
AU3122693A (en) 1993-05-21
AU661360B2 (en) 1995-07-20
DE69233402D1 (de) 2004-09-23
EP0667901B2 (de) 2008-10-15
CA2312667C (en) 2002-11-19
JP2877788B2 (ja) 1999-03-31
JPH10150994A (ja) 1998-06-09
EP0667901B1 (de) 2004-08-18
DE69233402T2 (de) 2005-09-15
ES2227513T3 (es) 2005-04-01
ATE274055T1 (de) 2004-09-15
NO317625B1 (no) 2004-11-29
WO1993008207A1 (en) 1993-04-29
NO980030L (no) 1998-01-05
FI981765A0 (fi) 1998-08-17

Similar Documents

Publication Publication Date Title
DK0667901T4 (da) Hidtil ukendt cytokin
DE3773293D1 (de) Weiche intraokulare linse.
DE69009901D1 (de) Lichtleiter.
FI892020A (fi) Fack foer is och iskuber formade i detta.
DE3685004D1 (de) Intraokulare linse.
DE68916079D1 (de) Intraokulare Linse.
FI894671A0 (fi) Reglerbar faestanordning.
DE69007332D1 (de) Optische Verstärkungseinrichtung mit niedrigem Rauschen.
DE68917796D1 (de) Intraokulare Linse.
DE68909704T2 (de) Optischer Verstärker mit reduzierter Nichtlinearität.
DE3788518T2 (de) Lärmisolierung mit lichtreflektierender Oberfläche.
ES1006699Y (es) Quemador protesico orientable.
NO910287L (no) Flerfokal intraokulaer linse.
NO882944L (no) Intraokulaer linse med justerbar styrke.
DE69128032T2 (de) Automatische Einstellung der optischen Ausgangsleistung von mehreren optischen Sendern
DK162319C (da) Reproduktionsapparat med skanderende lyskilde
ATE61725T1 (de) Faltbare intraokulare linse.
DK356689A (da) Optisk forstaerker med nedsat ulinearitet